MedTrace Logo

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

NCT00348348 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1161

Last updated 2015-03-24

Study results available
· View outcomes & findings →

Summary

This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.

Conditions

  • Acute Bacterial Conjunctivitis

Interventions

DRUG

Besifloxacin

Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days

DRUG

Moxifloxacin solution

Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Timothy Comstock, OD · Bausch & Lomb Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-07-31
Completion
2007-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00348348 on ClinicalTrials.gov